GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

Blood

Volumn 120, Issue 2, 2012, Pages 395-403

  Greif, Philipp A ^a,b   Dufour, Annika ^a   Konstandin, Nikola P ^a,b   Ksienzyk, Bianka ^a   Zellmeier, Evelyn ^a,b   Tizazu, Belay ^a,b   Sturm, Jutta ^a,b   Benthaus, Tobias ^a   Herold, Tobias ^a   Yaghmaie, Marjan ^a,b,h   Dörge, Petra ^c   Hopfner, Karl Peter ^a   Hauser, Andreas ^a   Graf, Alexander ^a   Krebs, Stefan ^a   Blum, Helmut ^a   Kakadia, Purvi M ^a,g   Schneider, Stephanie ^a   Hoster, Eva ^a   Schneider, Friederike ^a   Stanulla, Martin ^c   Braess, Jan ^d   Sauerland, Maria Cristina ^e   Berdel, Wolfgang E ^e   Büchner, Thomas ^e   Woermann, Bernhard J ^f   Hiddemann, Wolfgang ^a,b   Spiekermann, Karsten ^a,b   Bohlander, Stefan K ^a,b,g   more..

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Oncology and Hematology   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f German Society of Hematology and Oncology   (Germany)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; DNA METHYLTRANSFERASE 3A; TRANSCRIPTION FACTOR GATA 2; UNCLASSIFIED DRUG; ZINC FINGER 1; ZINC FINGER PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; CLINICAL ARTICLE; DNA BINDING; EXOME; GENE SEQUENCE; GENETIC ASSOCIATION; HEMATOPOIESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMOGENESIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION;

EID: 84864054209     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-403220     Document Type: Article

References (52)

1. Swerdlow, Harris. WHO classification on Tumours of the Haematopoietic and Lymphoid Tissues. Geneva, Switzerland: World Health Organiztion Press; 2008.
2. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
3. Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570-577.
4. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28(16):2739-2747.
5. Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009;100(8):1343-1346.
6. Taskesen E, Bullinger L, Corbacioglu A, et al. Prognostic impact, concurrent genetic mutations and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469-2475.
7. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088-3091.
8. Kato N, Kitaura J, Doki N, et al. Two types of C/EBP{alpha} mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models. Blood. 2011; 117(1):221-233.
9. Bereshchenko O, Mancini E, Moore S, et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. Cancer Cell. 2009;16(5):390-400.
10. Kirstetter P, Schuster MB, Bereshchenko O, et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell. 2008;13(4):299-310. (Pubitemid 351446194)
11. Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res. 2005;11(4):1372-1379.
12. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
13. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011; 29(21):2889-2896.
14. Masuda S. DNMT3A mutations in acute myeloid leukemia: impact on low-risk patients with CEBPA mutations. J Clin Oncol. 2011;29(34):4592-4593.
15. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29(5):475-486.
16. Tsai FY, Keller G, Kuo FC, et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature. 1994;371(6494):221-226. (Pubitemid 24293019)
17. Tsai FY, Orkin SH. Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood. 1997;89(10):3636-3643. (Pubitemid 27227086)
18. Persons DA, Allay JA, Allay ER, et al. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood. 1999;93(2): 488-499. (Pubitemid 29035730)
19. Rodrigues NP, Boyd AS, Fugazza C, et al. GATA-2 regulates granulocyte-macrophage progenitor cell function. Blood. 2008;112(13):4862- 4873.
20. Huang Z, Dore LC, Li Z, et al. GATA-2 reinforces megakaryocyte development in the absence of GATA-1. Mol Cell Biol. 2009;29(18):5168-5180.
21. Zhang SJ, Ma LY, Huang QH, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2008;105(6):2076-2081.
22. Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10):1012-1017.
23. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011;43(4):309-315.
24. Büchner T, Berdel WE, Schoch C, et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24(16):2480-2489. (Pubitemid 46655599)
25. Braess J, Spiekermann K, Staib P, et al. Dosedense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood. 2009; 113(17):3903-3910.
26. Gregory BD, O'Malley RC, Lister R, et al. A link between RNA metabolism and silencing affecting Arabidopsis development. Dev Cell. 2008;14(6): 854-866.
27. Lister R, O'Malley RC, Tonti-Filippini J, et al. Highly integrated single-base resolution maps of the epigenome in Arabidopsis. Cell. 2008;133(3): 523-536.
28. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-1760.
29. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-2079.
30. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26(6):841-842.
31. Koboldt DC, Chen K, Wylie T, et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics. 2009;25(17):2283-2285.
32. Greif PA, Eck SH, Konstandin NP, et al. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia. 2011;25(5):821-827.
33. Greif PA, Yaghmaie M, Konstandin NP, et al. Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia. 2011;25:1519-1522.
34. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics. 2010;26(16):2069-2070.
35. Robinson JT, Thorvaldsdottir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
36. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
37. Marková J, Michková P, Burčková K, et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol. 2012;88(2): 128-135.
38. Bates DL, Chen Y, Kim G, Guo L, Chen L. Crystal structures of multiple GATA zinc fingers bound to DNA reveal new insights into DNA recognition and self-association by GATA. J Mol Biol. 2008; 381(5):1292-1306.
39. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486-501.
40. Cobb BS, Morales-Alcelay S, Kleiger G, Brown KE, Fisher AG, Smale ST. Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding. Genes Dev. 2000;14(17):2146-2160.
41. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
42. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191):110-114. (Pubitemid 351630327)
43. Rocquain J, Gelsi-Boyer V, Adelaide J, et al. Alteration of cohesin genes in myeloid diseases. Am J Hematol. 2010;85(9):717-719.
44. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood. 2005;106(6):2113-2119. (Pubitemid 41291728)
45. Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil GS. Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Mol Cell Biol. 2005;25(2):706-715. (Pubitemid 40096591)
46. Zhang SJ, Shi JY, Li JY. GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism. Leuk Res. 2009;33(8):1141-1143.
47. Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood. 2011; 118(10):2656-2658.
48. Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet. 2011;43(10):929-931.
49. Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011;118(10):2653-2655.
50. Wölfler A, Danen-van Oorschot AA, Haanstra JR, et al. Lineage-instructive function of C/EBPalpha in multipotent hematopoietic cells and early thymic progenitors. Blood. 2010;116(20):4116-4125.
51. Trainor CD, Ghirlando R, Simpson MA. GATA zinc finger interactions modulate DNA binding and transactivation. J Biol Chem. 2000;275(36): 28157-28166.
52. Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU. 1. Nat Genet. 2004;36(6):624-630. (Pubitemid 38715991)